YOLFTbeta
Abivax S.A.

Abivax S.A.

0RA9 · LSE

79.10EUR-3.40 (-4.12%)

Price History

Full chart

Market Stats

Previous Close82.50
Open81.25
Day Range79.00 – 82.05
52-Week Range60.70 – 139.00
Volume89
Market Cap873.07M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.47
Dividend Yield0.00%
Beta-0.25
50-Day Avg11.44
200-Day Avg13.25

About

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Company Details

  • CEOMr. Marc M. P. de Garidel M.B.A.
  • Employees98
  • Headquarters7-11 Boulevard Haussmann, Paris, France, 75009, UK
  • Websitehttps://www.abivax.com

Leadership

  • Mr. Marc M. P. de Garidel M.B.A.CEO & Director · b. 1958
  • Mr. Didier BlondelEVP, CFO & Board Secretary · b. 1964
  • Dr. David Zhang Ph.D.Chief Strategy Officer · b. 1968
  • Dr. Keith M. Fournier Ph.D.Senior Vice President of Global Regulatory Affairs
  • Mr. Michael Nesrallah M.B.A.Chief Commercial Officer
  • Dr. Maurus de la Rosa Ph.D.Senior Vice President of Research
  • Mr. Ivan Nunez-PachecoGlobal Head of Patient Services
  • Ms. Heather DeanGlobal Head of Sales, Accounts & Commercial Operations
  • Mr. Jeffrey N. HaasGlobal Head of Market Access & Pricing

Financials

Income Statement

Currency: EUR2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue74.87K189.00K228.00K151.00K356.00K815.00K-7.00K14.00K4.20M4.48M4.49M10.79M-
Growth (%)-+152.43%+20.63%-33.77%+135.76%+128.93%-100.86%+300.00%+29921.43%+6.50%+0.38%+140.20%-
Cost of Revenue124.49K3.28M151.00K66.00K93.00K99.00K80.00K66.00K156.00K485.00K707.00K1.10M1.07M
Gross Profit-124.49K-3.09M77.00K85.00K263.00K716.00K-87.00K-52.00K4.05M3.99M4.49M-1.10M-1.07M
Gross Margin-166.27%-1634.39%33.77%56.29%73.88%87.85%1242.86%-371.43%96.29%89.16%100.00%-10.19%-
Operating Expense01.97M18.46M18.31M14.71M20.55M33.19M39.54M56.23M59.78M131.87M184.33M249.55M
Operating Income-124.49K-5.05M-18.38M-18.22M-14.45M-19.84M-33.27M-39.59M-52.19M-55.79M-127.38M-185.43M-250.63M
Operating Margin-166.27%-2674.07%-8063.16%-12066.89%-4059.27%-2434.11%475357.14%-282821.43%-1241.66%-1246.36%-2834.99%-1718.24%-
EBITDA-7.37M-5.00M-18.47M-18.17M-14.06M-18.95M-33.22M-39.53M-42.20M-57.71M-127.25M-167.68M-249.55M
EBITDA Margin-9849.55%-2648.15%-8100.44%-12033.11%-3948.60%-2325.52%474500.00%-282357.14%-1003.93%-1289.30%-2832.21%-1553.76%-
Net Income-124.49K-5.08M-15.95M-14.31M-11.22M-15.82M-30.63M-37.55M-41.36M-60.74M-147.74M-176.24M-336.10M
Net Income Margin-166.27%-2687.83%-6997.37%-9475.50%-3152.53%-1941.47%437628.57%-268221.43%-983.99%-1357.02%-3288.23%-1633.08%-
R&D-3.76M15.27M15.46M10.85M15.89M29.01M34.53M47.20M48.30M103.18M146.53M177.76M
R&D as % of Total Revenue-1991.53%6696.05%10237.75%3046.63%1950.18%-414385.71%246614.29%1123.05%1078.98%2296.37%1357.78%-
Interest Expense168.93K110.76K168.00K30.00K39.00K539.00K1.64M2.32M3.21M3.93M15.82M14.11M28.51M
Interest Expense % of Total Revenue225.63%58.60%73.68%19.87%10.96%66.13%-23442.86%16557.14%76.37%87.89%352.21%130.75%-

Balance Sheet

Currency: EUR2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets40.00K37.97M76.27M60.60M53.81M54.05M51.73M71.30M110.36M75.54M327.06M205.23M584.34M
Total Liabilities10.37K4.03M7.51M6.09M9.90M25.30M39.95M66.63M81.59M68.36M131.05M164.64M129.14M
Total Equity29.63K33.94M68.76M54.51M43.92M28.74M11.78M4.67M28.77M7.19M196.01M40.58M455.20M
Cash40.00K1.22M119.00K7.94M1.88M8.00M9.77M29.30M60.70M26.95M251.94M144.22M516.68M
Total Debt2.32M2.09M3.41M2.52M262.00K10.90M20.74M33.98M53.45M39.71M74.47M96.19M32.09M
Net Debt-40.00K869.00K3.29M-5.41M-1.62M2.90M10.98M4.69M-7.25M12.76M-177.48M-48.03M-484.59M

Cash Flow

Currency: EUR2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--3.31M-14.90M-15.61M-8.45M-14.60M-27.47M-29.82M-45.66M-57.93M-97.13M-153.59M-162.09M
Investing Cash Flow--43.00K-1.02M-94.00K-105.00K-254.00K-370.00K-575.00K-1.46M-12.04M-10.49M7.58M-13.72M
Financing Cash Flow-5.94M52.13M-438.00K2.60M10.83M24.61M49.93M78.51M36.23M335.29M35.90M553.80M
Capital Expenditure043.00K1.02M721.00K979.00K763.00K941.00K898.00K1.64M323.00K265.00K640.00K142.00K
Free Cash Flow--3.35M-15.93M-16.33M-9.43M-15.37M-28.41M-30.72M-47.30M-58.26M-97.39M-154.23M-162.23M
FCF to OCF-101.30%106.88%104.62%111.59%105.22%103.43%103.01%103.60%100.56%100.27%100.42%100.09%

Earnings

Report DateMar 31, 2025Sep 8, 2025Sep 30, 2025Mar 23, 2026Mar 31, 2026Sep 21, 2026Mar 22, 2027
EPS Estimate-------
EPS Actual-0.83-0.76-2.10-1.04-0.61-1.47-
Surprise-------
Timing-After-hours-After-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap873.07M
Enterprise Value6.63B
Trailing P/E0.00
Forward P/E0.00
Price / Sales191.04
Price / Book0.00
EPS-2.47
Book Value4.59
Revenue (TTM)4.67M
Gross Profit (TTM)4.67M
EBITDA-291.55M
Profit Margin0.00%
Operating Margin-8617.93%
Return on Equity-252.35%
Return on Assets-62.88%
Shares Outstanding9.98M
Shares Float69.03M
Beta-0.25
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%